Uncategorized
Vertex drops mRNA cystic fibrosis program over ‘tolerability’ issues
Vertex Pharmaceuticals said it has dropped development of an mRNA-based cystic fibrosis therapy, after facing challenges delivering the genetic medicine similar to those that have troubled other parts of the field.
The Boston-based company